Literature DB >> 10454778

Treatment practices of FSGS among North American pediatric nephrologists.

V M Vehaskari1.   

Abstract

A survey of North American pediatric nephrologists was conducted to assess the variability in the treatment of primary steroid-resistant focal segmental glomerulosclerosis (FSGS) of native kidneys. The most widely used immunosuppressive drug was cyclosporin A, with 73.9% using it often or sometimes. Only 44.3% used intravenous methylprednisolone combined with an alkylating agent at least sometimes; the use of methylprednisolone without cytotoxic drugs was slightly more common. Prolonged oral steroid therapy (>3 months) was used often or sometimes by 50.3%. The use of angiotensin converting enzyme inhibitors was very common, while lipid-lowering agents were rarely used. The variability in the treatment of FSGS most likely results from lack of evidence-based information and underscores the need for controlled pediatric multicenter treatment trials.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10454778     DOI: 10.1007/s004670050613

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  9 in total

1.  Response to cyclosporine in steroid-resistant nephrotic syndrome: discontinuation is possible.

Authors:  Ilka Klaassen; Bünyamin Özgören; Carolin E Sadowski; Kristina Möller; Michael van Husen; Anja Lehnhardt; Kirsten Timmermann; Folke Freudenberg; Udo Helmchen; Jun Oh; Markus J Kemper
Journal:  Pediatr Nephrol       Date:  2015-04-24       Impact factor: 3.714

Review 2.  New therapies in steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome.

Authors:  Michael van Husen; Markus J Kemper
Journal:  Pediatr Nephrol       Date:  2011-01-13       Impact factor: 3.714

3.  Association of steroid and cyclosporin resistance in focal segmental glomerulosclerosis.

Authors:  Ibrahim F Shatat; Morris Schoeneman; Joseph T Flynn; Robert P Woroniecki
Journal:  Pediatr Nephrol       Date:  2007-02-10       Impact factor: 3.714

Review 4.  The management of idiopathic nephrotic syndrome in children.

Authors:  Elisabeth Hodson
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

5.  Fifteen-year remission of a steroid-resistant nephrotic syndrome sustained by cyclosporine A.

Authors:  Jens Drube; Christoph Geerlings; Ruth Taylor; Michael Mengel; Jochen H H Ehrich
Journal:  Pediatr Nephrol       Date:  2007-01-18       Impact factor: 3.714

Review 6.  Steroid elimination is coming of age.

Authors:  Minnie Sarwal
Journal:  Pediatr Nephrol       Date:  2005-10-20       Impact factor: 3.714

Review 7.  Corticosteroid-resistant nephrotic syndrome with focal and segmental glomerulosclerosis : an update of treatment options for children.

Authors:  Jochen H H Ehrich; Lars Pape; Mario Schiffer
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

8.  Intravenous pulse cyclophosphamide--is it effective in children with steroid-resistant nephrotic syndrome?

Authors:  Hammad O Alshaya; Jaudah A Al-Maghrabi; Jameela A Kari
Journal:  Pediatr Nephrol       Date:  2003-09-17       Impact factor: 3.714

9.  Pulse cyclophosphamide therapy for steroid-resistant focal segmental glomerulosclerosis in children.

Authors:  Abdullah A Al Salloum
Journal:  Ann Saudi Med       Date:  2004 Jan-Feb       Impact factor: 1.526

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.